Objective To investigate whether the timing of secondary or primary progression is different between patients with familial and nonfamilial multiple sclerosis (MS).
Methods Information on the family history of 313 patients with MS was taken from our prospective hospital-based database. We used Kaplan—Meier analyses and Cox regression models to evaluate differences between familial and nonfamilial MS in several endpoint measures. We investigated the risk of developing secondary progression in all patients with a relapsing—remitting disease onset, the length of the relapsing—remitting phase and age at onset of progression in patients with secondary progressive MS and the age at disease onset in patients with primary progressive MS (PPMS).
Results Among the primary progressive patients, those with familial MS had a significantly younger age at disease onset than patients with nonfamilial MS (mean 33.04 years versus mean 37.73 years in nonfamilial MS, P = 0.02). There were no significant differences between familial and nonfamilial MS patients in any other investigated measure.
Conclusions Familial MS appears related to the time of disease onset in PPMS. Patients with familial PPMS may be an important patient group for future genetic research in MS. Multiple Sclerosis 2008; 14: 300—306. http://msj.sagepub.com
Minderhoud JM , van der Hoeven JH, Prange AJCourse and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study . Acta Neurol Scand1988; 78: 10-5.
7.
Kremenchutzky M., Rice GP, Baskerville J., Wingerchuk DM, Ebers GCThe natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain2006 ; 129: 584-94.
8.
Koch M., Mostert J., Heersema D., De Keyser J.Progression in multiple sclerosis: further evidence of an age dependent process . J Neurol Sci2007; 255: 35-41.
9.
Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GCTwin concordance and sibling recurrence rates in multiple sclerosis . Proc Natl Acad Sci USA2003; 100: 12877-82.
10.
Ebers GC, Koopman WJ, Hader W., Sadovnick AD, Kremenchutzky M., Mandalfino P. et al. The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis. Brain2000; 123: 641-9.
11.
Poser CM, Paty DW, Scheinberg L., McDonald WI, Davis FA, Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227-31.
12.
Weinshenker BG, Bulman D., Carriere W., Baskerville J., Ebers GCA comparison of sporadic and familial multiple sclerosis. Neurology1990; 40: 1354-58.
13.
Cottrell DA , Kremenchutzky M., Rice GP, Koopman WJ, Hader W., Baskerville J. et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis . Brain1999; 122: 625-39.
14.
Tremlett H. , Paty D., Devonshire V.The natural history of primary progressive MS in British Columbia, Canada. Neurology2005; 65: 1919-23.
15.
Polymeropoulos MH, Lavedan C., Leroy E., Ide SE, Dehejia A., Dutra A. et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease . Science1997; 276: 2045-47.
Revesz T., Kidd D., Thompson AJ, Barnard RO, McDonald WIA comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain1994; 117: 759-65.
18.
Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry1997; 63: 736-42.
